NR4A1 and breast carcinoma: Based on the CSCO guidelines, NET may be considered in patients with hormone receptor–positive (HR+) breast cancer patients who require preoperative neoadjuvant therapy but are not candidates for chemotherapy, are temporarily ineligible for surgery, or do not require immediate surgery.